Melanoma Research Foundation’s Post

❓ Is capturing more real-world Quality of Life and Tolerability data going to help with regulatory submissions 3 years from now? ❓ Why should I care about the "Parking Lot" effect if the FDA accepts it? ❓ How are changes in Oncology trials going to change how we need to conduct ePRO studies? Join us at 9AM EST for a fireside chat with Ari Gnanasakthy to get some answers to these questions! https://lnkd.in/eMKZs2z3

For patients, drug development timelines are not fast enough. At Viracta, we are actively working to accelerate our clinical trial timelines to meet the needs of patients living with EBV-associated cancer today. #TeamViracta will be carrying this early 2024 energy throughout the year.  Read more about our clinical trial updates and outlook for 2024 here 👇 https://lnkd.in/gdCzUdxc #news #EBV #lymphoma #clinicaltrials

Clinical research trials in #melanoma may help improve the way doctors treat, prevent and diagnose melanoma. To understand more about clinical trials, we encourage you to review this infographic: https://buff.ly/4aGi7Te, developed in partnership with Bristol Myers Squibb (BMS). Learn more about BMS clinical trials for melanoma patients – https://buff.ly/43MfoFT

#DidYouKnow – there are hundreds of clinical trials that melanoma patients can join. You may be able to join a clinical trial before or after you’ve tried other FDA-approved treatments & you will get the standard of care that is the usual FDA-approved treatment for your melanoma subtype. We invite you to review this clinical trial infographic, developed in partnership with Bristol Myers Squibb, to learn more about clinical trials - https://buff.ly/43MfoFT

Did you catch some familiar faces on Cincinnati’s Local 12 this past weekend?  CTI’s Medical Director, Richard Curry, MD, and CEO and Chairman, Timothy Schroeder, had the opportunity to sit down with local experts and Medical Reporter, Liz Bonis, to discuss cancer breakthroughs in the healthcare field. Greater Cincinnati has become a prevalent region for clinical research organizations, doctors, and advocates for cancer research, with significant strides made over the past decade. Curry and Schroeder focused on the recent BXQ-350 drug development in clinical trials from Bexion Pharmaceuticals. Aiming to fight cancer and stop neuropathy, a common side effect of chemotherapy. Check out the full report with this link: https://lnkd.in/gnRPwcAt To participate in the ongoing trial at our Clinical Research Center (CRC), visit our website https://lnkd.in/dQ7xux6Y We’re proud to have strong leadership and medical expertise on the CTI team working to #MoveMedicineForwad.  #MovingMedicineForward #AdvancingHealthcareSoltions #CRO #ThinkGlobalActLocal #ClinicalResearch #ClinicalTrials #LeadershipInTheField #BexionPharmaceuticals #BXQ350 #StopNeuropathology #FightCancer #CommonChemoSideEffects #WKRC #Local12 

Sysmex Inostics partners with pharma and clinicians to offer comprehensive #NGS testing services for clinical trials, expediting #oncology drug development and improving patient outcomes. Our ultrasensitive assays are utilized to support following applications in clinical trials: • inform therapy selection, • identify targetable resistance, • monitor tumor response, • detect minimal residual disease, • enable dose escalation/de-escalation studies. Learn more about our assays and capabilities: https://hubs.la/Q02HqC2r0 #ClinicalTrialSupport #targetedpanels #ctDNA #cfRNA

Join Predicine at the 2024 Biomarker and Companion Diagnostics Conference in San Diego on Feb. 8-9! Predicine will present and reveal our innovative oncology liquid biopsy testing in global markets, from lab testing to CDx.  • Case study 1 - MRD - Personalized and actionable MRD (PredicineBEACON™) vs panel-based, methylation MRD (PredicineALERT™)  • Case study 2 - Treatment selection - PredicineCARE™ for genomic profiling  • Global trials and CDx - Supporting US, China, EU, Japan and ROW oncology trials through centralized and decentralized testing, and global CDx development    Connect with Predicine at Booth Ex–18 and explore our innovative liquid biopsy solutions that support global clinical trials, companion diagnostics development, and commercialization. Schedule a meeting with the Predicine team: https://lnkd.in/dTJ9tkAu    Learn more about Predicine: https://lnkd.in/gndzmpGH     #diagnostics #oncology #NGS #liquidbiopsy #MRD #ctDNA #CDx 

On September 16, 2024, FDA released a guidance draft designed to provide sponsors of cancer drugs who contemplate global clinical development programs with suggestions for strengthening the quality of evidence provided by multiregional trials. There are specific recommendations for planning, designing, conducting, and analyzing MRCTs that will provide data relevant to U.S. cancer patients and U.S. medical practice . Although the guidance offers best practices, it is not legally enforceable unless specific regulatory requirements are cited. #CancerTreatment #OncologyResearch #ClinicalTrials #FDAApproval #DrugDevelopment #GlobalTrials #MRCTs #CancerDrugs #PharmaGuidelines #RegulatoryAffairs

We've successfully completed the full recruitment of our Phase 2 trial of SNT-5055, a pan-LOX inhibitor combined with ruxolitinib, aimed at treating the bone marrow cancer myelofibrosis. The trial, which began in December 2023 across 19 sites in the USA, Australia, South Korea, and Taiwan, has now dosed its 15th patient and exceeded the one-month treatment threshold for 12 patients required for FDA safety evaluation. No drug-related dropouts or serious adverse reactions have been observed. Interim results are expected in December 2024, coinciding with the ASH Annual Meeting, potentially paving the way for pivotal FDA discussions in early 2025. The full 12-month data set will be available in Q3 2025. CEO Gary Phillips said: “I’d like to thank the haematology clinics, investigators and the Syntara clinical team for achieving this significant milestone in such a timely fashion. We now look forward to presenting our interim data later in the year and building a solid foundation for the next stage of discussions with the FDA and potential strategic partners. Read the full ASX Announcement here: https://lnkd.in/g7d9fsqP #SNT #Syntara #ClinicalTrials #SNT5055 #Ruxolitinib #Myelofibrosis #BoneMarrowCancer #CancerResearch #FDAEvaluation #Phase2Trial #OncologyResearch #DrugDevelopment

The Sarcoma Foundation of America is hosting a "Sarcoma Drug Repurposing Webinar" and we would like to invite you to join us. Our colleague, Timothy Stuhlmiller, has been invited as a key speaker at this important event. Jan 18, 2024 1PM - 2:30PM EST This webinar, in collaboration with the CDRC Critical Path Institute (C-Path) Sarcoma Task Force, spotlights an innovative initiative. It delves deep into repurposing existing medications to revolutionize treatment options for sarcoma patients. With a focus on leveraging real-world data, this project underscores the potential of existing drugs in new therapeutic applications. 💡 Why Attend? - Discover cutting-edge approaches in sarcoma research. - Engage with leading experts in the field, including Timothy Stuhlmiller of xCures, Brandi Felser of Sarcoma Foundation of America, William Tap of Memorial Sloan Kettering Cancer Center and Lennie Woods of Clear Cell Sarcoma Foundation - Learn about the integration of real-world data in accelerating cost-effective treatments. - Contribute to a transformative discussion impacting the sarcoma community. Join the conversation and be part of this change. 🔗 Reserve your spot now! https://lnkd.in/gEBVyzdu #SarcomaResearch #DrugRepurposing #PatientEngagement #xCures #Innovation #HealthcareCollaboration